$29.33
+2.9%STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
STAA โข NASDAQ
| STAAR Surgical Company Income Statement | Jan 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Jan 2021 | Jan 2020 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
239.4M | 313.9M | 322.4M | 284.4M | 230.5M | 163.5M | 150.2M | 124M | 90.6M | 82.4M | 77.1M | 75M | 72.2M | 63.8M | 62.8M | 55M | 75.3M | 74.9M | 59.4M | 56.3M | |
GROSS PROFIT | ||||||||||||||||||||
(62.5M) | (74.3M) | (69.8M) | (61M) | (51.8M) | (45.1M) | (38.2M) | (32.4M) | (26.3M) | (24.1M) | (24.4M) | (26.2M) | (21.9M) | (19.5M) | (20.4M) | (19.9M) | (33.5M) | (34.8M) | (30.1M) | (29.8M) | |
176.9M | 239.6M | 252.7M | 223.4M | 178.6M | 118.4M | 112M | 91.5M | 64.3M | 58.4M | 52.7M | 48.8M | 50.3M | 44.3M | 42.4M | 35.1M | 41.9M | 40.1M | 29.3M | 26.4M | |
OPERATING INCOME | ||||||||||||||||||||
(222.8M) | (252.2M) | (224.6M) | (179.6M) | (145.3M) | (111.6M) | (100.1M) | (84.9M) | (67.9M) | (71M) | (58.1M) | (56.9M) | (49.6M) | (45.5M) | (39.6M) | (37.7M) | (45.6M) | (60.5M) | (43.4M) | (40M) | |
(183.6M) | (198.2M) | (180.2M) | (143.6M) | (111.4M) | (79.7M) | (74.8M) | (62.9M) | (48.8M) | (50.7M) | (43.3M) | (44.4M) | (42.7M) | (39.1M) | (33.7M) | (31.3M) | (40M) | (42.8M) | (36.7M) | (33.3M) | |
(39.3M) | (54M) | (44.4M) | (36M) | (33.9M) | (31.9M) | (25.3M) | (22M) | (19.1M) | (20.3M) | (14.8M) | (12.4M) | (6.7M) | (6.4M) | (5.9M) | (5.7M) | (5.9M) | (7.9M) | (6.7M) | (7.1M) | |
-45.9M | -12.6M | 28.1M | 43.8M | 33.3M | 6.8M | 11.9M | 6.6M | -3.6M | -12.7M | -5.3M | -8M | 700K | -1.2M | 2.8M | -2.6M | -3.7M | -20.4M | -14.1M | -13.6M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (38K) | (0.0) | (0.0) | (0.0) | (112K) | (115K) | (128K) | (154K) | (170K) | (291K) | (523K) | (896K) | (1.3M) | (901K) | (0.0) | (0.0) | |
4.6M | 5.9M | 7M | 2.4M | -38K | 238K | 988K | 165K | -112K | -112K | -78K | -103K | -111K | -232K | -491K | -853K | -1.3M | -741K | 0.0 | 0.0 | |
-71K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (715K) | (628K) | (470K) | (0.0) | (381K) | (486K) | (0.0) | (0.0) | (700K) | -238K | (9.8M) | (0.0) | -331K | |
-36.4M | 3.6M | 5.6M | 1.8M | -2M | 1.5M | 1.2M | 44K | 1.3M | 211K | -268K | -618K | 414K | 701K | -79K | -1.1M | -741K | -1.3M | -1M | 95K | |
-82.3M | -9.1M | 33.7M | 45.6M | 31.3M | 8.3M | 13M | 6.6M | -2.3M | -12.4M | -5.6M | -8.6M | 1.1M | -519K | 2.7M | -3.7M | -4.7M | -21.7M | -15.2M | -13.5M | |
NET INCOME | ||||||||||||||||||||
-1.8M | (11.2M) | (12.3M) | (5.9M) | (3.8M) | (2.4M) | -1M | (1.7M) | -157K | -315K | (928K) | -253K | (716K) | (1.2M) | (1.4M) | (432K) | (1.5M) | (1.5M) | (843K) | (1.5M) | |
-80.4M | -20.2M | 21.3M | 39.7M | 27.5M | 5.9M | 14M | 5M | -2.1M | -12.1M | -6.5M | -8.4M | 398K | -1.8M | 1.3M | 53K | -6.2M | -23.2M | -16M | -15M |
STAA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q2 Q2 | May 13, 2026 | April 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | May 04, 2026 | May 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2026 FY FY | March 03, 2026 | January 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 02, 2026 | February 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 15, 2026 | January 14, 2026 | 2026 |
Continue your STAA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.